GE HEALTHCARE TECHNOLOGY
GEHCNASDAQTrading Snapshot
- Day Range
- $65.49 β $66.97
- 52-Week Range
- $58.75 β $89.77
- Volume
- $2.54B
- Avg Volume
- $3.35B
- Shares Outstanding
- 451.7M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $20.63B
- Last Q Revenue
- $5.29B
- P/E Ratio
- 15.2
- P/S Ratio
- 1.4x
- EPS (TTM)
- $4.35
- Dividend Yield
- 0.21%
- Dilution (1yr)
- +0.3%
Why Investors Own GEHC
- βHigh-growth profile β revenue up -6.4% YoY with expanding US Equity exposure.
- βHealthy economics β 62% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GE HEALTHCARE TECHNOLOGY
GEHCAbout GE HEALTHCARE TECHNOLOGY
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals β molecular tracers labeled with radioisotopes β injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
GE HEALTHCARE TECHNOLOGY tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift GEHC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
GE HEALTHCARE TECHNOLOGY announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.